DK3030264T3 - Bispecifikke monovalente fc-diabodies, som kan binde cd32b og cd79b, og anvendelser heraf - Google Patents
Bispecifikke monovalente fc-diabodies, som kan binde cd32b og cd79b, og anvendelser heraf Download PDFInfo
- Publication number
- DK3030264T3 DK3030264T3 DK14834798.2T DK14834798T DK3030264T3 DK 3030264 T3 DK3030264 T3 DK 3030264T3 DK 14834798 T DK14834798 T DK 14834798T DK 3030264 T3 DK3030264 T3 DK 3030264T3
- Authority
- DK
- Denmark
- Prior art keywords
- domain
- seq
- polypeptide chain
- diabody
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Claims (13)
1. Bispecifik monovalent Fc-diabody, hvori den bispecifikke monovalente Fc-diabody specifikt kan binde til en epitop af CD32B og til en epitop af CD79b og har et IgG Fc-domæne, hvori den bispecifikke monovalente Fc-diabody omfatter en første polypeptidkæde, en anden polypeptidkæde og en tredje polypeptidkæde, hvori den første og den anden polypeptidkæde er kovalent bundet til hinanden, og den første og den tredje polypeptidkæde er kovalent bundet til hinanden, og hvori: A. den første polypeptidkæde i den N-terminale til C-terminale retning omfatter: i. et domæne 1, der omfatter: (1) et subdomæne (1A), der omfatter et cysteinholdigt peptid (SEQ ID NO:1); og (2) et subdomæne (IB), der omfatter en polypeptidportion af et IgG Fc-domæne, som har CH2- og CH3-domæner i et IgG-immunoglobulin-Fc-område; ii. et domæne 2, der omfatter: (1) et subdomæne (2A), der omfatter et VL-domæne i et monoklonalt antistof, som kan binde til CD32B (VLcd32b) (SEQ ID NO:11); og (2) et subdomæne (2B), der omfatter et VH-domæne i et monoklonalt antistof, som kan binde til CD79b (VHCd791d) (SEQ ID NO:14), hvori subdomænerne (2A) og (2B) er adskilt fra hinanden af en peptidlinker (Linker 2) (SEQ ID N0:4); iii. et domæne 3, hvori domænet 3 er et E-coil-domæne (SEQ ID NO:7) eller et K-coil-domæne (SEQ ID NO:8), hvori domænet 3 er adskilt fra domænet 2 af en peptidlinker (SEQ ID N0:5); og iv. et C-terminalt spacerpeptid (SEQ ID NO:6); B. den anden polypeptidkæde i den N-terminale til C-terminale retning omfatter: i. et domæne 1, der omfatter: (1) et subdomæne (1A), der omfatter et VL-domæne i et monoklonalt antistof, som kan binde til CD7 9b (VLcd791d) (SEQ ID NO:13); og (2) et subdomæne (IB), der omfatter et VH-domæne i et monoklonalt antistof, som kan binde til CD32B (VHcd32b) (SEQ ID NO:12); hvori subdomænerne (1A) og (IB) er adskilt fra hinanden af en peptidlinker (Linker 2) (SEQ ID N0:4); ii. et domæne 2, hvori domænet 2 er et K-coil-domæne (SEQ ID NO:8) eller et E-coil-domæne (SEQ ID NO:7), hvori domænet 2 er adskilt fra domænet 1 af en peptidlinker (SEQ ID NO:5); og hvori domænet 3 i den første polypeptidkæde og domænet 2 i den anden polypeptidkæde ikke begge er E-coil-domæner eller begge K-coil-domæner; og C. den tredje polypeptidkæde i den N-terminale til C-terminale retning omfatter et domæne 1, der omfatter: (1) et subdomæne (1A), der omfatter et cysteinholdigt peptid (SEQ ID NO:1); og (2) et subdomæne (IB), der omfatter en polypeptidportion af et IgG Fc-domæne, som har CH2- og CH3-domæner i et IgG-immunoglobulin-Fc-område; og hvori: (a) polypeptidportionerne af IgG Fc-domænerne i den første og tredje polypeptidkæde danner IgG Fc-domænet; (b) VL-domænet i den første polypeptidkæde og VH-domænet i den anden polypeptidkæde danner et antigenbindende domæne, som specifikt kan binde til en epitop af CD32B; og (c) VH-domænet i den første polypeptidkæde og VL-domænet i den anden polypeptidkæde danner et antigenbindende domæne, som specifikt kan binde til en epitop af CD79b.
2. Bispecifik monovalent Fc-diabody ifølge krav 1, hvori subdomænet (IB) i den første polypeptidkæde omfatter en sekvens, der er forskellig fra sekvensen i subdomænet (IB) i den tredje polypeptidkæde.
3. Bispecifik monovalent Fc-diabody ifølge krav 1, hvori subdomænet (IB) i den første polypeptidkæde har aminosyresekvensen ifølge SEQ ID NO:9, og subdomænet (IB) i den tredje polypeptidkæde har aminosyresekvensen ifølge SEQ ID NO:10.
4. Bispecifik monovalent Fc-diabody ifølge krav 1, hvori subdomænet (IB) i den første polypeptidkæde har aminosyresekvensen ifølge SEQ ID NO:10, og subdomænet (IB) i den tredje polypeptidkæde har aminosyresekvensen ifølge SEQ ID NO: 9.
5. Bispecifik monovalent Fc-diabody ifølge et af kravene 1-2, hvori domænet 1 i den første polypeptidkæde og/eller domænet 1 i den tredje polypeptidkæde omfatter en variant CH2-CH3-sekvens, som har ændret binding til en Fcy-receptor.
6. Bispecifik monovalent Fc-diabody ifølge et af kravene 1-5, hvori domænet 3 i den første polypeptidkæde omfatter en E-coil (SEQ ID NO: 7) , og domænet 2 i den anden polypeptidkæde omfatter en K-coil (SEQ ID NO:8).
7. Bispecifik monovalent Fc-diabody ifølge et af kravene 1-5, hvori domænet 3 i den første polypeptidkæde omfatter en K-coil (SEQ ID NO:8), og domænet 2 i den anden polypeptidkæde omfatter en E- coil (SEQ ID NO:7).
8. Bispecifik monovalent Fc-diabody, hvori det bispecifikke monovalente Fc-diabody specifikt kan binde til en epitop af CD32B og til en epitop af CD79b og har et IgG Fc-domæne, hvori den bispecifikke monovalente Fc-diabody omfatter: (1) en første polypeptidkæde, som har aminosyresekvensen ifølge SEQ ID NO:15 (2) en anden polypeptidkæde, som har aminosyresekvensen ifølge SEQ ID NO:16, og (3) en tredje polypeptidkæde, som har aminosyresekvensen i følge SEQ ID NO: 17, hvori aminosyreresterne 1-10 i den tredje polypeptidkæde er peptid 1 (SEQ ID NO:l), og aminosyreresterne 11-227 i den tredje polypeptidkæde er CH2- og CH3-domænerne i et IgG-antistofs Fc-område (SEQ ID NO:10) hvori den første og den anden polypeptidkæde er kovalent bundet til hinanden ved hjælp af en første disulfidbinding, og den første og den tredje polypeptidkæde er kovalent bundet til hinanden ved hjælp af en anden disulfidbinding.
9. Farmaceutisk sammensætning, der omfatter den bispecifikke monovalente Fc-diabody ifølge et af kravene 1-8 og en fysiologisk acceptabel bærer.
10. Bispecifik monovalent-Fc diabody ifølge et hvilket som helst af kravene 1-8 eller i den farmaceutiske sammensætning ifølge krav 9 til anvendelse ved behandling af en inflammatorisk sygdom eller tilstand.
11. Bispecifik monovalent Fc-diabody eller farmaceutisk sammensætning til anvendelse ifølge krav 10, hvori den inflammatoriske sygdom eller tilstand er en autoimmun sygdom.
12. Bispecifik monovalent Fc-diabody eller farmaceutisk sammensætning til anvendelse ifølge krav 11, hvori den autoimmune sygdom er systemisk lupus erythematosus (SLE).
13. Bispecifik monovalent Fc-diabody eller farmaceutisk sammensætning til anvendelse ifølge krav 10, hvori den inflammatoriske sygdom eller tilstand er graft versus hostsygdom (GvHD).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864217P | 2013-08-09 | 2013-08-09 | |
| US201361866416P | 2013-08-15 | 2013-08-15 | |
| US201361869519P | 2013-08-23 | 2013-08-23 | |
| US201361907525P | 2013-11-22 | 2013-11-22 | |
| PCT/US2014/049848 WO2015021089A1 (en) | 2013-08-09 | 2014-08-06 | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3030264T3 true DK3030264T3 (da) | 2019-04-23 |
Family
ID=52461888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14834798.2T DK3030264T3 (da) | 2013-08-09 | 2014-08-06 | Bispecifikke monovalente fc-diabodies, som kan binde cd32b og cd79b, og anvendelser heraf |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10344092B2 (da) |
| EP (1) | EP3030264B1 (da) |
| JP (1) | JP6395834B2 (da) |
| KR (1) | KR102294018B1 (da) |
| CN (2) | CN105611943B (da) |
| AU (1) | AU2014306105B2 (da) |
| CA (1) | CA2920021C (da) |
| CL (1) | CL2016000293A1 (da) |
| DK (1) | DK3030264T3 (da) |
| DO (1) | DOP2016000044A (da) |
| EA (1) | EA033658B1 (da) |
| ES (1) | ES2720730T3 (da) |
| GE (1) | GEP201706794B (da) |
| HU (1) | HUE043229T2 (da) |
| IL (1) | IL244009B (da) |
| MX (1) | MX2016001741A (da) |
| PE (1) | PE20160508A1 (da) |
| PH (1) | PH12016500242A1 (da) |
| PL (1) | PL3030264T4 (da) |
| PT (1) | PT3030264T (da) |
| SG (1) | SG11201600855VA (da) |
| TN (1) | TN2016000042A1 (da) |
| TW (1) | TW201536805A (da) |
| UA (1) | UA116479C2 (da) |
| WO (1) | WO2015021089A1 (da) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| CN106349390B (zh) * | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
| EP2840091A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| TWI681971B (zh) | 2014-08-06 | 2020-01-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類Ｉｇβ抗體 |
| EP3180358B1 (en) | 2014-08-13 | 2020-04-01 | SuppreMol GmbH | Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor |
| EP3201227A4 (en) | 2014-09-29 | 2018-04-18 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
| WO2016149710A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
| AU2016232693B2 (en) | 2015-03-19 | 2021-08-12 | Duke University | HIV-1 neutralizing antibodies and uses thereof |
| US10450368B2 (en) | 2015-03-19 | 2019-10-22 | Duke University | HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies) |
| WO2017011414A1 (en) * | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| WO2017011413A1 (en) * | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| KR20180038045A (ko) * | 2015-08-17 | 2018-04-13 | 마크로제닉스, 인크. | B7-h3과 cd3에 결합할 수 있는 이중특이적 1가 디아바디, 및 그것의 사용 |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| UY37127A (es) * | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| AU2017278329A1 (en) * | 2016-06-07 | 2019-01-03 | Macrogenics, Inc. | Methods for the use of CD32B x CD79B-binding molecules in the treatment of inflammatory diseases and disorders |
| WO2018060979A1 (fr) | 2016-09-30 | 2018-04-05 | Centre National De La Recherche Scientifique | Marqueurs membranaires |
| EP3585431A4 (en) | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| CA3089877A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| BR112020023432A2 (pt) * | 2018-05-18 | 2021-02-23 | Macrogenics, Inc. | molécula de ligação a gp41, composição farmacêutica e método para tratar ou prevenir infecção por hiv-1 em um indivíduo que precisa do mesmo |
| CA3149209A1 (en) * | 2019-07-30 | 2021-02-04 | Provention Bio, Inc. | Methods and compositions for reducing immunogenicity by non-depletional b cell inhibitors |
| EP4010371A1 (en) | 2019-08-08 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
| WO2021207681A1 (en) * | 2020-04-10 | 2021-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted reduction of activated immune cells |
| IL302473A (en) * | 2020-11-01 | 2023-06-01 | Provention Bio Inc | Methods and preparations for the treatment of lupus |
| WO2023122798A2 (en) * | 2021-12-23 | 2023-06-29 | Provention Bio, Inc. | Methods and compositions for treating barth syndrome |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US192737A (en) | 1877-07-03 | Improvement in corn-planters | ||
| DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US4752601A (en) | 1983-08-12 | 1988-06-21 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin FC receptors |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US4800078A (en) | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| GB8916400D0 (en) | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
| AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| JP2571874B2 (ja) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス，インコーポレイテッド | タンパク質マイクロスフェア組成物 |
| US5364930A (en) | 1990-10-16 | 1994-11-15 | Northwestern University | Synthetic C1q peptide fragments |
| GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| ATE221379T1 (de) | 1991-05-01 | 2002-08-15 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
| AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| PT682710E (pt) | 1993-02-10 | 2004-03-31 | Unilever Nv | Processo de isolamento utilizando proteinas imobilizadas com capacidades de ligacao especificas |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| WO1995004069A1 (en) | 1993-07-30 | 1995-02-09 | Affymax Technologies N.V. | Biotinylation of proteins |
| GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
| DE69522216T2 (de) | 1994-05-13 | 2002-05-02 | Biovation Ltd | Zielzellen-bindende chimäre Peptide |
| WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| JP2000507912A (ja) | 1995-08-31 | 2000-06-27 | アルカームズ コントロールド セラピューティックス，インコーポレイテッド | 作用剤の徐放性組成物 |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
| EP0885002B1 (en) | 1996-03-04 | 2011-05-11 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6025485A (en) | 1997-02-14 | 2000-02-15 | Arcaris, Inc. | Methods and compositions for peptide libraries displayed on light-emitting scaffolds |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
| US6455263B2 (en) | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| SE9802213D0 (sv) | 1998-06-18 | 1998-06-18 | Amersham Pharm Biotech Ab | A method for the removal/purification of serum albumins and means for use in the method |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2386574A3 (en) | 1999-01-15 | 2012-06-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| DE19937264A1 (de) | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
| AU2001260153B2 (en) | 2000-03-24 | 2006-08-17 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| EP3569610A3 (en) | 2000-12-12 | 2020-03-18 | Medlmmune, LLC | Molecules with extended half lives, compositions and uses thereof |
| US20030199671A1 (en) | 2001-04-18 | 2003-10-23 | Rondon Isaac Jesus | Binding molecules for Fc-region polypeptides |
| JP4381140B2 (ja) | 2001-10-12 | 2009-12-09 | シェーリング コーポレイション | 免疫応答を調節するための二重特異性抗体の使用 |
| ATE481109T1 (de) | 2001-10-16 | 2010-10-15 | Us Gov Health & Human Serv | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden |
| US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
| CA2484182A1 (en) | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| WO2003101485A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| CA2490009A1 (en) | 2002-06-21 | 2003-12-31 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US20090017023A1 (en) | 2002-08-14 | 2009-01-15 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| ES2562177T3 (es) | 2002-09-27 | 2016-03-02 | Xencor Inc. | Variantes de Fc optimizadas y métodos para su generación |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2007525149A (ja) | 2003-01-13 | 2007-09-06 | マクロジェニクス，インコーポレーテッド | 可溶性ＦｃγＲ融合タンパク質およびその使用法 |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| EP2154157A3 (en) | 2004-01-12 | 2010-04-28 | Applied Molecular Evolution Inc. | FC region variants |
| WO2005097175A2 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
| US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
| EP1747237A4 (en) | 2004-04-16 | 2008-05-21 | Macrogenics Inc | SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME |
| JP2007536932A (ja) | 2004-05-10 | 2007-12-20 | マクロジェニクス，インコーポレーテッド | ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| US7432419B2 (en) | 2004-05-14 | 2008-10-07 | Los Alamos National Security, Llc | Compositions and methods for the treatment of Pierce's disease |
| NZ582684A (en) | 2004-06-18 | 2011-05-27 | Ambrx Inc | Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker |
| CA2779559A1 (en) | 2004-08-04 | 2006-02-23 | Applied Molecular Evolution Inc. | Variant fc regions |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| EP1835935A4 (en) | 2004-12-30 | 2009-06-17 | Univ Rockefeller | COMPOSITIONS AND METHODS FOR IMPROVED DENDRITIC CELL REPRODUCTION AND FUNCTION |
| US20060193849A1 (en) | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
| CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| EP1919503B1 (en) | 2005-08-10 | 2014-09-24 | MacroGenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| US7786270B2 (en) | 2006-05-26 | 2010-08-31 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| JP5764290B2 (ja) | 2006-06-26 | 2015-08-19 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体およびその使用法 |
| US20080112961A1 (en) | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| CN107226864A (zh) | 2007-06-21 | 2017-10-03 | 宏观基因有限公司 | 共价双抗体及其用途 |
| KR101940059B1 (ko) * | 2008-12-19 | 2019-01-18 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이의 용도 |
| MX2011014008A (es) | 2009-06-26 | 2012-06-01 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| PT2486141T (pt) | 2009-10-07 | 2018-05-09 | Macrogenics Inc | Polipéptidos contendo uma região fc que apresenta uma função efectora melhorada, devido a modificações do grau de fucosilação, e métodos para a sua utilização |
| MX339622B (es) | 2010-08-02 | 2016-06-02 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
| US20140088019A1 (en) | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
| RS58765B1 (sr) | 2011-05-21 | 2019-06-28 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| BR112013029892A2 (pt) * | 2011-05-21 | 2016-12-20 | Macrogenics Inc | polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada |
| RU2721707C2 (ru) * | 2013-03-14 | 2020-05-21 | Макродженикс, Инк. | Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
-
2014
- 2014-06-08 UA UAA201601792A patent/UA116479C2/uk unknown
- 2014-08-06 CN CN201480045937.9A patent/CN105611943B/zh active Active
- 2014-08-06 TN TN2016000042A patent/TN2016000042A1/en unknown
- 2014-08-06 MX MX2016001741A patent/MX2016001741A/es active IP Right Grant
- 2014-08-06 JP JP2016533386A patent/JP6395834B2/ja active Active
- 2014-08-06 ES ES14834798T patent/ES2720730T3/es active Active
- 2014-08-06 PL PL14834798T patent/PL3030264T4/pl unknown
- 2014-08-06 SG SG11201600855VA patent/SG11201600855VA/en unknown
- 2014-08-06 AU AU2014306105A patent/AU2014306105B2/en active Active
- 2014-08-06 GE GEAP201414076A patent/GEP201706794B/en unknown
- 2014-08-06 PT PT14834798T patent/PT3030264T/pt unknown
- 2014-08-06 CA CA2920021A patent/CA2920021C/en active Active
- 2014-08-06 CN CN202110078461.0A patent/CN112898432B/zh active Active
- 2014-08-06 KR KR1020167005947A patent/KR102294018B1/ko active IP Right Grant
- 2014-08-06 DK DK14834798.2T patent/DK3030264T3/da active
- 2014-08-06 PE PE2016000227A patent/PE20160508A1/es unknown
- 2014-08-06 TW TW103126989A patent/TW201536805A/zh unknown
- 2014-08-06 EP EP14834798.2A patent/EP3030264B1/en active Active
- 2014-08-06 WO PCT/US2014/049848 patent/WO2015021089A1/en active Application Filing
- 2014-08-06 EA EA201690325A patent/EA033658B1/ru not_active IP Right Cessation
- 2014-08-06 US US14/909,820 patent/US10344092B2/en active Active
- 2014-08-06 HU HUE14834798A patent/HUE043229T2/hu unknown
-
2016
- 2016-02-04 PH PH12016500242A patent/PH12016500242A1/en unknown
- 2016-02-05 DO DO2016000044A patent/DOP2016000044A/es unknown
- 2016-02-05 CL CL2016000293A patent/CL2016000293A1/es unknown
- 2016-02-08 IL IL244009A patent/IL244009B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3030264T3 (da) | Bispecifikke monovalente fc-diabodies, som kan binde cd32b og cd79b, og anvendelser heraf | |
| EP3161004B1 (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| KR102269584B1 (ko) | Gpa33 및 cd3에 결합할 수 있는 이중특이성 1가 디아바디 및 그것의 용도 | |
| KR20180038045A (ko) | B7-h3과 cd3에 결합할 수 있는 이중특이적 1가 디아바디, 및 그것의 사용 | |
| CA2986415A1 (en) | Anti-cd137 antibodies | |
| KR20170063755A (ko) | Cd19 및 cd3에 결합할 수 있는 이중-특이적 1가 디아바디, 및 그것의 사용 | |
| JP2022120061A (ja) | 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子 | |
| US20220372144A1 (en) | Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof | |
| US20170157251A1 (en) | Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof | |
| CN112533945A (zh) | 优化的结合gp41的分子及其用途 | |
| JP7128819B2 (ja) | Ａｄａｍ９結合分子、およびその使用方法 | |
| JP2022538102A (ja) | 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子 | |
| RU2772434C2 (ru) | Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств | |
| BR112016002738B1 (pt) | Diacorpo de fc monovalente biespecífico, composição farmacêutica, uso do diacorpo de fc monovalente biespecífico, e uso da composição farmacêutica |